间皮素作为癌症免疫治疗的生物标志物和治疗靶点
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于预测三阴性乳腺癌患者免疫检查点抑制剂应答的联合生物标志物
英文原题：Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer.
查看英文原题
Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
IMAGiC 与 iTIL 联合作为生物标志物，可指导转移性 TNBC 免疫治疗的临床决策。
中文摘要
患者与方法
分析31例接受免疫治疗的转移性TNBC患者。采用定量实时PCR测定IMAGiC检测中4种免疫相关基因的mRNA表达。使用AI驱动的空间TIL分析工具Lunit SCOPE IO检测并定量TIL。
结果
根据IMAGiC评分截点，将患者分为IMAGiC应答者组和无应答者组。IMAGiC应答者组的临床应答者（完全缓解[CR]或部分缓解[PR]）比例显著高于无应答者组（50%比15.3%，P=0.05）。计算IMAGiC组别和评分、PD-L1 CPS、iTIL及sTIL对免疫治疗应答的预测曲线下面积（AUC）。IMAGiC组别和评分的AUC分别为0.684和0.632。联合IMAGiC组别和iTIL水平后，AUC最高，达到0.755。
结论
联合使用IMAGiC和iTIL作为生物标志物，可指导转移性TNBC免疫治疗的临床决策。
展开英文摘要原文
PATIENTS AND METHODS
Thirty-one metastatic TNBC patients receiving immunotherapy were analyzed. For measuring expression levels of the mRNA of four immune-related genes in the IMAGiC test, quantitative real-time polymerase chain reaction was used. TIL detection and quantification were conducted using Lunit SCOPE IO, which is an AI-powered spatial TIL analyzer.
RESULTS
Patients were classified into IMAGiC responder and non-responder groups according to IMAGiC score cut-off value. There were significantly more clinical responders [complete (CR) or partial (PR) response] in the IMAGiC responder group than in the IMAGiC non-responder group (50% vs. 15.3%, p =0.05). Area under the curve (AUC) values were calculated to examine the predictive value of the IMAGiC score, PD-L1 CPS, iTILs, and sTILs, for response to immunotherapy. The AUC values of the IMAGiC group and score were 0.684 and 0.632, respectively. When the IMAGiC group and iTIL level were combined, the highest AUC value of 0.755 was obtained.
CONCLUSION
The combination of IMAGiC and iTILs as a biomarker can guide clinical decisions in the immunotherapy of metastatic TNBCs.
论文信息
- 作者
- Kim HG、Kang SY、Kim KM、Kim JY、Park YH、Ahn JS、Im YH、Lim Y
- 第一作者单位
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.South Korea
- 通讯作者单位
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; eunyoon.cho@samsung.com.South Korea
- 期刊
- Anticancer research2025 Jun
- 原文标识
- PubMed 40425338 · DOI 10.21873/anticanres.17629